89BIO INC. - COMMON STOCK

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

21 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

89bio to Participate in the 2023 Cantor Global Healthcare Conference

20 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

05 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

09 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12 Jul 2023 16:30:00 By Nasdaq GlobeNewswire

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

24 Jun 2023 05:05:00 By Nasdaq GlobeNewswire

Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress

24 Jun 2023 05:01:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023

07 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

23 May 2023 08:00:01 By Nasdaq GlobeNewswire

89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

04 May 2023 16:05:00 By Nasdaq GlobeNewswire

89bio to Participate in Upcoming Investor Conferences

02 May 2023 08:00:01 By Nasdaq GlobeNewswire

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock

24 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

22 Mar 2023 16:16:12 By Nasdaq GlobeNewswire

89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

22 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

10 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

04 Mar 2023 13:30:00 By Nasdaq GlobeNewswire

89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

21 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

89bio to Participate in the SVB Securities Global Biopharma Conference

08 Feb 2023 08:00:02 By Nasdaq GlobeNewswire

89bio Provides Business Update and Outlook for 2023

04 Jan 2023 16:01:00 By Nasdaq GlobeNewswire